Methylene blue-treated fresh-frozen plasma: What is its contribution to blood safety?

Transfusion

Volumn 43, Issue 9, 2003, Pages 1322-1329

  Williamson, Lorna M ^a   Cardigan, Rebecca ^b   Prowse, Chris V ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; METHYLENE BLUE;

ANTIVIRAL ACTIVITY; BLOOD TRANSFUSION; INFECTION PREVENTION; LIGHT EXPOSURE; PHOTODYNAMICS; REVIEW; SAFETY;

ANTIVIRAL AGENTS; BLOOD COAGULATION; BLOOD PRESERVATION; HUMANS; METHYLENE BLUE; PLASMA;

EID: 0038692734     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00483.x     Document Type: Review

References (52)

1. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998;38:1027.
2. Provisional surveillance summary of the West Nile Virus epidemic - United States January-November, 2002. MMWR 2002;51:1129-33.
3. Chapman J. Virus inactivation of plasma by methylene blue photoinactivation: approaches and toxicology. Transfus Today 1994;20:2-4.
4. Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995;24:73-85.
5. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002;16:61-6.
6. Wagner S, Storry JR, Mallory DA, et al. Red cell alterations associated with virucidal methylene blue treatment. Transfusion 1993;33:30-6.
7. Wagner SJ, Robinette D, Storry J, et al. Differential sensitivities of viruses in red cell suspensions to methylene blue photo sensitization. Transfusion 1994;34:521-6.
8. Abe H, Yamada-Ohnishi Y, Hirayama J, et al. Elimination of both cell-free and cell-associated HIV infectivity in plasma by a filtration/ methylene blue photoinactivation system. Transfusion 2000;40:1081-7.
9. Chapman J. Viral inactivation of plasma by methylene blue photoinactivation: virology and plasma protein overview. Transfus Today 1994;22:2-5.
10. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991;60:207-13.
11. D'Antonio D, Di Gianfilippo R, Iacone A, et al. Methylene blue and high intensity light source inducing HCV RNA PCR negativity in plasma of two HCV positive patients. Transfusion 1999;39:24S.
12. Mohr H, Bachmann B, Klein-Struckmeier A, Lambrecht B. Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol 1997;65:441-5.
13. Muller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol 1998;56:239-45.
14. Iudicone P. Photodynamic treatment of fresh frozen plasma by methylene blue: effect on HIV, HCV and parvovirus B19. Infusion Ther Transfus Med 1999;26:262-6.
15. Achour A. Phenothiazines and prion diseases: a potential mechanism of action towards oxidative stress. Int J Antimicrob Agents 2002;20:305-6.
16. Zeiler T, Riess H, Wittmann G, et al. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994;34:685-9.
17. Inada Y, Hessel B, Blomback B. Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim Biophys Acta 1978;532:161-70.
18. Mohr H, Knuver-Hopf J, Lambrecht B, et al. No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Haematol 1992;65:224-8.
19. Tissot U, Hochstrasser D, Schneider B, et al. No evidence for protein modifications in fresh frozen plasma after photochemical treatment: an analysis by high-resolution two-dimensional electrophoresis. Br J Haematol 1994; 86:143-6.
20. Wieding JU, Rathgeber J, Zenjer D. Prospective, randomized trial and controlled study on solvent detergent versus methylene blue virus inactivated plasma. Transfusion 1999;39:23S.
21. Lorenz M, Muller M, Jablonka B, et al. High doses of methylene blue/ light treatment crosslink the A-alpha-subunit of fibrinogen: influence of this photooxidization on fibrinogen binding to platelets. Haemostasis 1998;28:17-24.
22. Parkkinen J, Vaaranen O, Vahtera E. Plasma ascorbate protects coagulation factors against photooxidation. Thromb Haemost 1996;75:292-7.
23. Aznar JA, Bonanad S, Montoro JM, et al. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000;79:156-60.
24. Cardigan R, Garwood M, Hornsey V, et al. Effect of freeze-thawing, leucocyte depletion, methylene blue (MB) treatment and removal on the quality of FFP. Vox Sang 2002;83:190.
25. AuBuchon JP, Pickard C, Herschel L, et al. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang 1998;74:1-6.
26. Riggert J, Humpe A, Legler TJ, et al. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Transfusion 2001 ;41:82-6.
27. Verpoort T, Chollet S, Lebrun F, et al. Elimination of methylene blue from photo-dynamically treated virus inactivated fresh-frozen plasma: the Blueflex filter. Trans Clinique Biologique 2001;8(Suppl 1):103s.
28. Hornsey VS, Drummond O, Young D, et al. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001;11:31-6.
29. Aznar JA, Molina R, Montoro JM. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 1999;39:748-50.
30. Cardigan R, Allford S, Williamson L. Levels of von Willebrand factor cleaving protease are normal in methylene blue treated fresh frozen plasma. Br J Haematol 2002;117:253-4.
31. Simonsen AC, Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma. Vox Sang 1999;77:210-7.
32. Hornsey VS, Krailadsiri, MacDonald S, et al. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol 2000;109:665-70.
33. Prowse CV, Hornsey V, Young D. Improving the yield of fibrinogen in cryoprecipitate prepared from methylene blue treated (MB) fresh frozen plasma. International Society of Blood Transfusion, Istanbul, 2003. Abstract 025.
34. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 1989;87:9N-15N.
35. Perrotta PL, Baril L, Tead C, et al. Effects of methylene blue-treated plasma on red cells and stored platelet concentrates. Transfusion 1999;39:63-9.
36. Garwood M, Cardigan R, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma (FFP). Transfusion 2003;43:1238-47.
37. Little AD Inc. National Toxicology Program. Executive summary of safety and toxicity information: methylene blue. Arthur D. Little, Cambridge, MA, 1990.
38. Tiboni GM, Giampetro F, Lamonaca D. The soluble guanylate cyclase inhibitor methylene blue evokes pre-term delivery and fetal growth retardation in a mouse model. In Vivo 2001;15:333-7.
39. Wagner SJ, Cifone MA, Murli H, et al. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion 1995;35: 407-15.
40. Pohl U, Mohr H. Virus Inactivation of plasma by methylene blue/light exposure: clinical experiences. Transfus Today 1994;21:2-3.
41. Pohl U, Wieding JU, et al. Treatment of patients with severe congenital coagulation factor V or Xi deficiency with methylene blue virus inactivated plasma. ISBT 5th Regional (European) Congress, Meeting Proceedings, Venice, Italy, 1995.
42. Pohl U, Becker M, et al. Methylene blue virus inactivated plasma in the treatment of patients with thrombotic thrombocytopenic purpura. ISBTVth Regional (European) congress, Meeting Proceedings, Venice, Italy, 1995.
43. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photo inactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001;41:1548-52.
44. Taborski U, Oprean N, Tessmann R, et al. Methylene blue/light-treated plasma and the disturbance of fibrin polymerization in vitro and in vivo: a randomized, double-blind clinical trial. Vox Sang 2000;78:P546.
45. Serious Hazards of Transfusion Annual Report, 2000-2001. SHOT Steering Committee, 2002.
46. Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: an unrecognized complication. Pediatrics 1996;97:717-21.
47. Pohl U, Becker B, Papstein C, et al. Methylene blue virus inactivated fresh frozen plasma in the treatment of patients with thrombotic thrombocytopenic purpura. Meeting Proceedings, Japan: International Society of Blood Transfusion, 1996.
48. De la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopic purpura. Br J Haematol 2001;114: 721-3.
49. Alfonso R, Lin C, Dupuis K, et al. Inactivation of viruses with preservation of coagulation function in fresh frozen plasma. Blood 1996;88:10, S1, 526a.
50. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion 2001;41:317-22.
51. Lillie RD. Conn's biological stains. Baltimore: Williams and Wilkins, 1991.
52. Budavari S (ed). The Merck index, 12th edn. Whitehouse Station (NJ): Merck and Co., 1996.